ChemoRadiotherapy with Or Without surgery followed by consolidation Durvalumab (CROWD): a phase IV feasibility trial
Key facts
- Where
- Amsterdam, HollandiaSee the site
- Phase
- 4. fázis
Where in Hollandia
- Amsterdam UMC StichtingAmsterdam, HollandiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amsterdam UMC Stichting
- Trial code
- EU 2024-511711-21-00
- Record updated
- 2024. december 12.
- Original description
-to assess the safety of surgery in patients with initially unresectable stage III NSCLC who are considered resectable by the multidisciplinary team within 12 weeks after finishing high-dose CRT -to assess the ability to proceed to durvalumab consolidation therapy after surgeryRead full original descriptionShow less
-to assess the safety of surgery in patients with initially unresectable stage III NSCLC who are considered resectable by the multidisciplinary team within 12 weeks after finishing high-dose CRT -to assess the ability to proceed to durvalumab consolidation therapy after surgery
Inclusion: Histologically or cytologically confirmed stage III (non-N3) NSCLC (TNM 8th edition), before start of chemoradiotherapy; In case of suspected N2-disease, mediastinal invasive staging (EUS, EBUS and/or mediastinoscopy) to prove N2 involvement before start of concurrent CRT is mandatory; Initial MDT recommendation for a non-surgical treatment comprising CRT followed by durvalumab.
Exclusion: Patients with TxN3 or M1 disease; The use of any CRT schemes other than those in ESMO recommendations (platinum doublet, 30 once-daily fractions of 2 Gy); Patients deemed inoperable based on cardiopulmonary function tests or comorbidity; Patients with known actionable genomic alterations.